Leukemic architecture as a framework for risk stratification in NPM1-mutated acute myeloid leukemia
NPM1-mutant leukemia subdivides into distinct subtypes requiring individualized treatment, not uniform favorable-risk protocols.
This review synthesizes integrative transcriptomic and epigenomic evidence showing NPM1c AML is not uniformly favorable-risk but comprises primitive and committed subtypes based on stemness programs, epigenetic lesions, and clonal hierarchies. The authors advocate for risk stratification that incorporates leukemic cell state and mutational hierarchy rather than NPM1 mutation status alone.
What the study was
- Study design
- narrative_review
- Category
- hematologic_malignancies
- Maturity
- Exploratory
- Journal
- Discov Oncol
Why it surfaced
Conceptually advances understanding of NPM1c AML heterogeneity with potential clinical relevance for risk stratification; well-synthesized review but lacks original data; WATCH for emerging clinical translation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.